

or a pharmaceutically acceptable salt thereof,  
wherein:

$R_1$  is a bond - , - , - ,

- , - , - , - , or - ,

wherein  $X$  is a halogen and  $Y$  is an alkyl group and  
wherein indicates bonding to  $R_2$  at any position  
and indicates bonding to  $R_2$  and the substituent  
at any position; and


$R_2$  is a bond, -  $(CY')_2n^-$  , -  $(CY')_2-CY'=CY')_n^-$  ,

-  $(CY')_2-CY'_2-CH=CH)_n^-$  , -  $(CY'=CY')_n^-$  , or -  $(CY')_2-C)_n^-$  ,

wherein  $Y'$  is hydrogen or an alkyl group and wherein  $n$  is 1 to 8; and



$R_3$  is -  $Y''$  , -  $OH$  , -  $NH_2$  , -  $N^+(Y'')_3$  , -  $COCH$  , -  $COO^-$  ,  
-  $SO_3H$  , -  $SO_3^-$  , -  $C-PO_3H_2$  or -  $C-PO_3H^-$  , wherein  $Y''$  is an alkyl group .

Fig. 1A



or a pharmaceutically acceptable salt thereof,  
wherein:

each  $R_1'$  is independently a bond,




wherein  $Y''$  is an alkyl group, and wherein indicates bonding to  $R_1'$  at any position and indicates bonding to  $R_1'$  and the  $R_1'$  phenyl substituent at any position;

each  $R_2'$  is independently a bond, or  $-(CH_2)_n-$   
wherein  $n$  is 1-4,


each  $R_3'$  is independently  $-Y''$ ,  $-Y'''$ ,  $-H$ ,  $-OH$ ,  $-OY''$ ,  $-NO_2$ ,  $-CN$ ,  $-NH_2$ ,  $-COOH$ ,  $-COY''$ ,  $-COO^-$ , or a heterocyclic group, wherein  $Y''$  is as defined above and  $Y'''$  is a primary, secondary, tertiary or quaternary amine.

Fig. 1B.

Fig. 1C



I



II

2023 RELEASE UNDER E.O. 14176

R<sub>1</sub> through R<sub>8</sub> are, independently, -H, alkyl, 2-hydroxyalkyl, methoxyalkyl,

halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid, alkyl ester of carboxylic acid, carboxylic acid, glucuronyl or glyceryl ester of carboxylic acid, 1,2-dihydroxyalkyl, acetyl, vinyl, glycosyl or, taurate, and

β, γ and δ are, independently, -H, acetyl, glycyl, benzoate,

phenylsulfonate, 2-, or 3-, or 4-N-alkyl-pyridyl, nitrophenyl, halophenyl, methoxyalkyl, halogen, nitro, cyano, trialkylammonium, formyl, amide of carboxylic acid.

Fig 1D

JOURNAL OF CLIMATE






Fig. 1E




or pharmaceutically acceptable salt thereof

wherein:

R<sub>1</sub> and R<sub>2</sub> are the same and are:




R<sub>3</sub> and R<sub>4</sub> are the same and are:



Y is halogen or -CO<sub>2</sub>X

each X is the same or different and is an alkyl and each R<sub>i</sub> is the same or different (preferably the same) and is H or alkyl.

Fig 1 F



I

or pharmaceutically acceptable salt thereof

wherein:

R<sub>1</sub> and R<sub>3</sub> are, independently:

-CO<sub>2</sub>C<sub>1-4</sub> alkyl; or

-CO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>CX<sub>3</sub>, wherein X is halogen and n = 1 to 3;

R<sub>2</sub> is:

-H

-C<sub>1-4</sub>alkyl

-COOH

-CO<sub>2</sub>C<sub>1-4</sub> alkyl,

-CO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>CX<sub>3</sub>, wherein X is halogen and n = 1 to 3,

-CON(CH<sub>3</sub>)<sub>2</sub>, or

-CX<sub>3</sub>, wherein X is halogen; and

R<sub>4</sub> is:

-H,

-C<sub>1-4</sub>alkyl

-COOH,

-CO<sub>2</sub>C<sub>1-4</sub> alkyl,


-CO<sub>2</sub>(CH<sub>2</sub>)<sub>n</sub>CX<sub>3</sub>, wherein X is halogen and n = 1 to 3,

-CON(CH<sub>3</sub>)<sub>2</sub>, or


-CX<sub>3</sub>, wherein X is halogen.

PRINTED IN U.S.A.

Fig 1G



I



or


II,

or pharmaceutically acceptable salt thereof,  
wherein




each R is, independently, a C<sub>1</sub>-C<sub>8</sub> alkyl group,  
and

each P is, independently, an electron  
withdrawing group or hydrogen.

2022-10-12 14:50:01




H H  
H G




**Figure 2A**


**B16 Melanoma tumor - SOD mimetic treatment**




**Figure 2B**



Effect of Radiation & AEOL 10113 on Mammary Adenocarcinoma




Tumor Growth Inhibition  
R3230 AC Mammary Adenocarcinoma in Fisher rats




**Figure 4**

Tumor growth inhibition (s.q. chambers)  
Dose = 6 mg/kg




Tumor Angiogenesis  
Dose = 6 mg/kg



2022-07-26 10:51:52

Figure 6



Catalytic Antioxidant Metalloporphyrin  
[MnTBAP]

Figure 7




Figure 8





Fig ure 9

A



B






Figure 10




1000 1250 1500 1750

2022-10-22 15:50:00


Figure 11




**Figure 12**




**Figure 13A**




**Figure 13B**




**Figure 14**






**Figure 15**

**FIGURE 16**  
**A549 3H-Thymidine uptake at 24 hours**




**Figure 17**



**Figure 18**

**INC-01 Blinded Mucositis Scores**



## Percentage of Study Days with Ulceration as Indicated by a Score of 3 or Greater

